Status:
RECRUITING
A Ketogenic Diet as a Complementary Treatment on Patients With High-grade Gliomas and Brain Metastases
Lead Sponsor:
Attikon Hospital
Conditions:
Brain
Cancer
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
The survival interval of patients with gliomas ranges between 12 to 15 months. Recent findings revealed that dietary interventions to reduce glucose and glycolytic pathways could have a therapeutic ef...
Detailed Description
Gliomas are invasive and aggressive tumors, which derive from glial or stem cells, and after neoplastic transformation, acquire glial cell characteristics. Treatment of high-grade gliomas includes mea...
Eligibility Criteria
Inclusion Criteria:
- Age 18-80
- Karnofsky Performance Score of 50 or more.
- Newly diagnosed, histologically confirmed glioblastoma grade 4, or secondary metastases or progression after surgical resection, radiation and chemotherapy.
- Normal function of liver and kidneys
- Ability to sign informed consent form
Exclusion Criteria:
- Diabetes mellitus
- Life expectancy >3 months
- Inability to adhere to diet
- Inability to give informed consent form
- Cholecystectomy last 1 year (before the study entry)
- Diagnosis of genetic disorder of fat metabolism
Key Trial Info
Start Date :
September 20 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 28 2026
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT05564949
Start Date
September 20 2022
End Date
February 28 2026
Last Update
May 31 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Arezina Kasti
Chaïdári, Athens, Greece, 12461
2
Attikon University General Hospital
Athens, Greece, 12462